[1] Shehab N, Lovegrove M C, Geller A I,et al. US emergency department visits for outpatient adverse drug events, 2013-2014 [J]. JAMA, 2016, 316(20): 2115-2125.
[2] 钟诗龙,韩雅玲,陈纪言,等. 氯吡格雷抗血小板治疗个体化用药基因型检测指南解读 [J]. 中国实用内科杂志,2015, 35(1): 38-41.
[3] 周 洲,孙艺红,张真路. 血小板功能检测在急性冠脉综合征患者抗血小板治疗中的应用专家共识 [J]. 中华医学杂志,2018, 98(22): 1743-1751.
[4] 王 迪,沈成兴. 基于血小板功能和基因检测的个体化抗血小板治疗进展 [J]. 中国循环杂志,2021, 36(6): 619-624.
[5] Zheng Y Y,Wu T T, Yang Y,et al. Personalized antiplatelet therapy guided by a novel detection of platelet aggregation function in stable coronary artery disease patients undergoing percutaneous coronary intervention: a randomized controlled clinical trial [J]. Eur Heart J Cardiovasc Pharmacother, 2020, 6(4): 211-221.
[6] Sibbing D, Aradi D, Alexopoulos D,et al. Updated expert consensus statement on platelet function and genetic testing for guiding P2Y(12) receptor inhibitor treatment in percutaneous coronary intervention [J]. JACC Cardiovasc Interv, 2019, 12(16): 1521-1537.
[7] 卢 聪,程 标. 血小板功能检测在经皮冠状动脉介入术后抗血小板治疗中的应用进展[J]. 实用医院临床杂志,2021, 18(3): 207-211.
[8] Jiang H,Wang H, Liang B,et al. Prognostic implication of systemic inflammatory state on antiplatelet effect in patients after percutaneous coronary intervention for ST-elevation myocardial infarction: a retrospective cohort study [J]. Medicine (Baltimore), 2021, 100(37): e27214.
[9] Page M J, Pretorius E. A champion of host defense: a generic large-scale cause for platelet dysfunction and depletion in infection [J]. Semin Thromb Hemost, 2020, 46(3): 302-319.
[10] Houck K L, Yuan H, Tian Y,et al. Physical proximity and functional cooperation of glycoprotein 130 and glycoprotein VI in platelet membrane lipid rafts [J]. J Thromb Haemost, 2019, 17(9): 1500-1510.
[11] Cavallari L H. Personalizing antiplatelet prescribing using genetics for patients undergoing percutaneous coronary intervention [J]. Expert Rev Cardiovasc Ther, 2017, 15(8): 581-589.
[12] Neumann F J, Sousa-Uva M, Ahlsson A,et al. 2018 ESC/EACTS guidelines on myocardial revascularization [J]. Eur Heart J, 2019, 40(2): 87-165.
[13] Tang Y D, Wang W, Yang M,et al. Randomized comparisons of double-dose clopidogrel or adjunctive cilostazol versus standard dual antiplatelet in patients with high posttreatment platelet reactivity: results of the creative trial [J]. Circulation, 2018, 137(21): 2231-2245.
[14] 李 兴,卢姿瑾,王晓冬,等. CYP2C19基因多态性联合血小板功能检测指导PCI术后患者抗血小板药物选择的效果观察 [J]. 首都医科大学学报,2020, 41(6): 960-964.
[15] Byrne R A, Joner M, Kastrati A. Stent thrombosis and restenosis: what have we learned and where are we going? The andreas grüntzig lecture ESC 2014 [J]. Eur Heart J, 2015, 36(47): 3320-3331.
[16] Collet J P, Thiele H, Barbato E,et al. 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation [J]. Eur Heart J, 2021, 42(14): 1289-1367.
[17] Sibbing D, Aradi D, Jacobshagen C,et al. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (Tropical-ACS): a randomised, open-label, multicentre trial [J]. Lancet, 2017, 390(14): 1747-1757.
[18] Cuisset T, Deharo P, Quilici J,et al. Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the topic (timing of platelet inhibition after acute coronary syndrome) randomized study [J]. Eur Heart J, 2017, 38(41): 3070-3078.
[19] Park M W, Kim C J, Kim M C,et al. A prospective, multicentre, randomised, open-label trial to compare the efficacy and safety of clopidogrel versus ticagrelor in stabilised patients with acute myocardial infarction after percutaneous coronary intervention: rationale and design of the talos-ami trial [J]. Eur Intervent, 2021, 16(14): 1170-1176.
[20] Hassan S S, Stankowski T, Marczak J,et al. Timing strategy of preoperative aspirin and its impact on early outcomes in patients undergoing coronary artery bypass grafting: a propensity score matching analysis [J]. J Surg Res, 2020, 246: 251-259.
[21] Vuilliomenet T, Gebhard C, Bizzozero C,et al. Discontinuation of dual antiplatelet therapy and bleeding in intensive care in patients undergoing urgent coronary artery bypass grafting: a retrospective analysis [J]. Interact Cardiovasc Thorac Surg, 2019, 28(5): 665-673.
[22] Mahla E, Suarez T A, Bliden K P,et al. Platelet function measurement-based strategy to reduce bleeding and waiting time in clopidogrel-treated patients undergoing coronary artery bypass graft surgery: the timing based on platelet function strategy to reduce clopidogrel-associated bleeding related to CABG (Target-CABG) study [J]. Circ Cardiovasc Interv, 2012, 5(2): 261-269.
[23] Mannacio V, Meier P, Antignano A,et al. Individualized strategy for clopidogrel suspension in patients undergoing off-pump coronary surgery for acute coronary syndrome: a case-control study [J]. J Thorac Cardiovasc Surg, 2014, 148(4): 1299-1306.
[24] Boer C, Meesters M I, Milojevic M,et al. 2017 EACTS/EACTA guidelines on patient blood management for adult cardiac surgery [J]. J Cardiothorac Vasc Anesth, 2018, 32(1): 88-120.